The Food and Drug Administration (FDA) on March 22 granted emergency use authorization (EUA) for Invivyd's monoclonal antibody to prevent COVID-19 in immunocompromised patients, which fills a gap following the withdrawal of Evusheld in January 2023.
Major bipartisan health bills, including changes to the pharmacy benefit manager (PBM) industry and hospital payment reforms, were excluded from the $1.2 trillion government funding bill after members failed to come to a last-minute agreement.
Experts say that focused planning and forecasting efforts helped avoid some of the worst-case scenarios. But there was still a significant number of severe outcomes, and there are still key areas of improvement – especially around vaccination.